Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (17086)	3/10/1998 3:00:00 PM
From: Henry Niman	Respond to of 32384

Tuck, Estrogen would definite put it back into the SERM camp. The IL-2 fusion protein is Interleukin-2 fused to a diptheria toxin. It binds to cells expressing IL-2 and then kills them. I assume that CTCL cells have an abundance of IL-2 receptors. LLY has a deal with SRGN and they have the rights to DAB389 IL-2 which is slated to go before the FDA fairly soon. The market would be relatively small and overlap with the initial Targretin indication. Thus, I thought that the indication would be of interest to LGND, while the market would be too small for LLY. As far as I know, the only SERM that LLY has is Evista. It's hard to imagine how LGND would get a piece of that action, unless it was something like a Canadian license (LGND already has a small sales force up there). However, I would think that if it's as straightforward as a Canadian license for Evista, then it would be signed already, unless its not approved there yet, and the timeline is delayed. Anyone know the status of Evista in Canada (or Europe?)?